Synthesis and P2Y receptor activity of nucleoside 5′-phosphonate derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 11, 2009, Pages 3002-3005

  Cosyn, Liesbet ^a   Calenbergh, Serge Van ^a   Joshi, Bhalchandra V ^b   Ko, Hyojin ^b   Carter, Rhonda L ^c   Kendall Harden, T ^c   Jacobson, Kenneth A ^b  

^a GHENT UNIVERSITY   (Belgium)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Agonist; G protein coupled receptors; Nucleotide; Phospholipase C; Purines; Pyrimidines

Indexed keywords

ADENOSINE 5' (DIPHOSPHO)PHOSPHONATE; BIS(URIDINE PHOSPHONATE); NUCLEOTIDE DERIVATIVE; OXYGEN; PHOSPHONIC ACID DERIVATIVE; PURINERGIC P2Y2 RECEPTOR; PURINERGIC P2Y4 RECEPTOR; UNCLASSIFIED DRUG; URIDINE 5' (DIPHOSPHO)PHOSPHONATE; URIDINE 5' (DIPHOSPHO)VINYLPHOSPHONATE; URIDINE 5' (GLUCOSE[1']PHOSPHO)PHOSPHONATE; URIDINE 5' METHYLENE PHOSPHONATE; URIDINE 5' PHOSPHO PHOSPHONATE; URIDINE DIPHOSPHATE;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; MOLECULAR INTERACTION;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CELL LINE, TUMOR; HUMANS; NUCLEOTIDES; RECEPTORS, PURINERGIC P2; RECOMBINANT PROTEINS; URIDINE DIPHOSPHATE; URIDINE TRIPHOSPHATE;

EID: 65149105731     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.04.027     Document Type: Article

References (21)

1. Abbracchio M.P., Burnstock G., Boeynaems J.M., Barnard E.A., Boyer J.L., Kennedy C., Fumagalli M., King B.F., Gachet C., Jacobson K.A., and Weisman G.A. Pharmacol. Rev. 58 (2006) 281
2. Jacobson K.A., Ivanov A.A., de Castro S., Harden T.K., and Ko H. Purinergic Signal. 5 (2009) 75
3. Gachet C. Thromb. Haemost. 99 (2008) 466
4. Nichols K.K., Yerxa B., and Kellerman D.J. Expert Opin. Investig. Drugs. 13 (2004) 47
5. Ivanov A.A., Costanzi S., and Jacobson K.A. J. Comput. Aided Mol. Des. 20 (2006) 417
6. Moro S., and Jacobson K.A. Curr. Pharmaceut. Des. 8 (2002) 99
7. Brunschweiger A., and Müller C.E. Curr. Med. Chem. 13 (2006) 289
8. Shaver S.R., Rideout J.L., Pendergast W., Douglas J.G., Brown E.G., Boyer J.L., Patel R.I., Redick C.C., Jones A.C., Picher M., and Yerxa B.R. Purinergic Signal. 1 (2005) 183
9. Besada P., Shin D.H., Costanzi S., Ko H.J., Mathé C., Gagneron J., Gosselin G., Maddileti S., Harden T.K., and Jacobson K.A. J. Med. Chem. 49 (2006) 5532
10. El-Tayeb A., Qi A., and Müller C.E. J. Med. Chem. 49 (2006) 7076
11. Ivanov A.A., Ko H., Cosyn L., Maddileti S., Besada P., Fricks I., Costanzi S., Harden T.K., Van Calenbergh S., and Jacobson K.A. J. Med. Chem. 50 (2007) 1166
12. Kim H.S., Ravi R.G., Marquez V.E., Maddileti S., Wihlborg A.-K., Erlinge D., Malmsjö M., Boyer J.L., Harden T.K., and Jacobson K.A. J. Med. Chem. 45 (2002) 208
13. Costanzi S., Joshi B.V., Maddileti S., Mamedova L., Gonzalez-Moa M.J., Marquez V.E., Harden T.K., and Jacobson K.A. J. Med. Chem. 48 (2005) 8108
14. Raju N., Smee D.F., Robins R.K., and Vaghefi M.M. J. Med. Chem. 32 (1989) 1307
15. Jung K.-Y., Hohl R.J., Wiemer A.J., and Wiemer D. Bioorg. Med. Chem. 8 (2008) 2501
16. Xu Y., Flavin M.T., and Xu Z.-Q. J. Org. Chem. 61 (1996) 7697
17. Nicholas R.A., Lazarowski E.R., Watt W.C., Li Q., and Harden T.K. Mol. Pharmacol. 50 (1996) 224
18. Bourdon D.M., Wing M.R., Edwards E.B., Sondek J., and Harden T.K. Methods Enzymol. 406 (2006) 489
19. Jones G.H., and Moffatt J.G. J. Am. Chem. Soc. 90 (1968) 5337
20. Fricks I., Maddiletti S., Carter R., Lazarowski E.R., Nicholas R.A., Jacobson K.A., and Harden T.K. J. Pharm. Exp. Therap. 325 (2008) 588
21. Ko H., Carter R.L., Cosyn L., Petrelli R., de Castro S., Besada P., Zhou Y., Cappellacci L., Franchetti P., Grifantini M., Van Calenbergh S., Harden T.K., and Jacobson K.A. Bioorg. Med. Chem. 16 (2008) 6319